CUE BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.63 USD | +2.52% |
|
+0.31% | -38.26% |
| May. 09 | Cue Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 08 | Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024 |
Chart calendar Cue Biopharma, Inc.
eb1286488d8c5a4.DkzY_DmwUH47VcdgqBqlfAc7fCz-MXTwrSHm_PX5_iM.bBOMs3rzKQpYAK0D7GuVTk1pFhW1dSuC52ePsYWYtWZ2JJTJYdQ4JncgtA~f161cb9c503f47a438da6d59a7e4bd8a
Upcoming events on Cue Biopharma, Inc.
Past events on Cue Biopharma, Inc.
| 2024-06-01 02:30 pm | American Society of Clinical Oncology Meeting - Abstract Number: 3553 |
| 2024-05-14 12:00 pm | Citizens JMP Life Sciences Conference |
| 2024-05-13 | PEGS Boston Summit - Poster Number: B023 |
| 2024-05-12 | PEGS Boston Summit - Poster Number: A028 |
| 2024-05-09 04:05 pm | Q1 2024 Earnings Release |
| 2024-04-08 04:30 pm | Q4 2023 Earnings Call |
| 2024-04-08 04:05 pm | Q4 2023 Earnings Release |
| 2024-03-01 04:35 pm | Multi-disciplinary Head and Neck Cancers Symposium - Poster #: 7 - Session III |
| 2024-02-13 09:20 am | Oppenheimer Healthcare Life Sciences Conference |
| 2023-12-05 11:30 am | JMP Securities Hematology and Oncology Summit |
| 2023-11-29 04:00 pm | Piper Sandler Healthcare Conference |
| 2023-11-14 01:50 pm | Stifel Healthcare Conference |
| 2023-11-09 04:30 pm | Q3 2023 Earnings Call |
| 2023-11-09 04:05 pm | Q3 2023 Earnings Release |
| 2023-11-04 12:00 pm | Society for Immunotherapy of Cancer Meeting - Abstract Number: 750 |
| 2023-11-04 12:00 pm | Society for Immunotherapy of Cancer Meeting - Abstract Number: 674 |
| 2023-10-31 | Society for Immunotherapy of Cancer Meeting |
| 2023-08-09 04:30 pm | Business Update Call |
| 2023-08-09 04:10 pm | Q2 2023 Earnings Release |
| 2023-06-21 04:45 pm | Federation of Clinical Immunology Societies Meeting |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 3,46 3,28 5.39% | 3,15 3,36 -6.08% | 14,9 9,21 62.31% | 1,25 1,20 3.96% | 5,49 4,84 13.52% | 10,5 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 0,00 - | -44,0 -43,2 -1.82% | -42,5 -48,0 11.55% | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -36,8 -37,9 3.04% | -45,0 -44,7 -0.77% | -43,7 -47,6 8.09% | -53,2 -50,3 -5.71% | -52,1 -53,1 1.82% | -52,6 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -36,3 -38,3 5.37% | -44,6 -44,2 -0.79% | -43,7 -47,1 7.38% | -53,0 -50,3 -5.36% | -50,7 -52,2 2.72% | -51,8 |
|
Net income Million USD | Released Forecast Spread | -36,7 -38,8 5.32% | -44,8 -44,2 -1.35% | -44,2 -47,1 6.33% | -53,0 -50,3 -5.36% | -50,7 -52,1 2.65% | -51,8 |
|
EPS USD | Released Forecast Spread | -1,66 -1,76 5.68% | -1,56 -1,52 -2.86% | -1,41 -1,49 5.37% | -1,49 -1,42 -4.75% | -1,11 -1,14 2.97% | -1,00 |
| Announcement Date | 12/03/20 | 09/03/21 | 16/03/22 | 21/03/23 | 28/03/24 | - |
Quarterly results
| Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 1,00 2,92 -65.78% | 0,03 1,13 -97.7% | 0,07 0,44 -84.56% | 0,15 0,10 45.76% | 0,19 1,95 -90.41% | 1,38 0,91 52.29% | 2,10 1,12 87.5% | 1,82 1,57 16.21% | 1,72 1,21 41.55% | 1,29 | 1,29 | 6,25 | 1,40 | 1,45 |
|
EBIT Million USD | Released Forecast Spread | -14,2 -14,1 -1.32% | -13,1 -14,5 9.49% | -11,0 -13,6 18.75% | -14,9 -12,0 -23.99% | -13,4 -12,9 -4.05% | -13,5 -13,7 1.49% | -11,4 -15,7 27.07% | -13,8 -13,2 -5.16% | -12,7 -14,0 9.45% | -13,7 | -15,1 | -11,2 | -17,8 | -18,8 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -14,3 -13,5 -5.91% | -13,2 -14,5 8.93% | -11,0 -13,5 19.05% | -14,6 -11,9 -22.19% | -13,1 -12,7 -3.53% | -13,2 -13,6 2.89% | -11,0 -15,6 29.36% | -13,4 -13,0 -3.1% | -12,3 -13,8 10.46% | -13,6 | -14,8 | -11,0 | -17,8 | -18,9 |
|
Net income Million USD | Released Forecast Spread | -14,3 -13,5 -5.91% | -13,2 -14,5 8.93% | -11,0 -13,5 19.05% | -14,6 -11,9 -22.19% | -13,1 -12,7 -3.53% | -13,2 -13,6 2.89% | -11,0 -15,6 29.36% | -13,4 -13,0 -3.1% | -12,3 -13,8 10.46% | -13,6 | -14,8 | -11,0 | -17,8 | -18,9 |
|
EPS USD | Released Forecast Spread | -0,44 -0,42 -4.76% | -0,37 -0,42 12.6% | -0,31 -0,38 19.13% | -0,38 -0,31 -22.58% | -0,29 -0,29 0% | -0,29 -0,31 4.92% | -0,24 -0,34 29.93% | -0,29 -0,28 -4.32% | -0,25 -0,28 11.35% | -0,27 | -0,26 | -0,21 | -0,35 | -0,36 |
| Announcement Date | 10/05/22 | 04/08/22 | 14/11/22 | 21/03/23 | 09/05/23 | 08/08/23 | 03/11/23 | 28/03/24 | 09/05/24 | - | - | - | - | - |
More events
Past sector events for Cue Biopharma, Inc.
| 2024-05-17 07:00 am | AUTOLUS THERAPEUTICS PLC: Q1 2024 Earnings Release |
| 2024-05-16 07:46 am | BIOCON LIMITED: Q4 2024 Earnings Release |
| 2024-05-16 01:00 am | ZEALAND PHARMA A/S: Q1 2024 Earnings Release |
| 2024-05-15 | LIGACHEM BIOSCIENCES INC.: Q1 2024 Earnings Release |
| 2024-05-15 08:05 am | THIRD HARMONIC BIO, INC.: Q1 2024 Earnings Release |
| 2024-05-15 07:00 am | CABALETTA BIO, INC.: Q1 2024 Earnings Release |
| 2024-05-14 | TAIMED BIOLOGICS INC.: Q1 2024 Earnings Release |
| 2024-05-14 04:05 pm | ENLIVEN THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-05-14 04:00 pm | ARCUTIS BIOTHERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-05-14 08:00 am | IMMUNOME, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- CUE Stock
- Calendar Cue Biopharma, Inc.
